NCT06403436View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 7, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Solid TumorAdult Solid TumorAdult DiseaseCancerNSCLCEGFRKRAS G12CSquamous Cell Lung Cancer
Interventions
DRUG

TT125-802

TT125-802 administered orally

Trial Locations (7)

1890

RECRUITING

Centre Hospitalier Universitaire Vaudois, Lausanne

6500

RECRUITING

Ente Ospedaliero Cantonale, Bellinzona

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

28223

RECRUITING

NEXT Oncology Madrid, Madrid

37203

RECRUITING

Sarah Cannon Research Institute Oncology Partners, Nashville

08023

RECRUITING

NEXT Oncology Barcelona, Barcelona

08035

RECRUITING

Vall d'Hebron Institute of Oncology, Barcelona

All Listed Sponsors
lead

TOLREMO therapeutics AG

INDUSTRY